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Abstract
Objective: Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to
etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid
arthritis (RA). Data from these trials were used to identify baseline characteristics associated with radiographic
progression and to build a matrix risk model for its prediction.
Methods: Patients with radiographic progression and baseline demographic and disease characteristic data were
pooled across the 3 phase III studies of each biosimilar and its reference product. Baseline demographics and
disease characteristics were evaluated for their relationship with radiographic progression (1-year mean change in
mTSS > 0); 3 factors were selected based on strongest Pearson’s correlation coefficient with the change in modified
Total Sharp Score. Univariate logistic regression was performed to assess the association between each baseline
factor and the rate of radiographic progression, with subsequent matrix model development performed using
multivariate logistic regression.
Results: A total of 1371 patients were included in the analysis, with a radiographic progression rate of 27.4%. The 3
baseline predictors of radiographic progression, based on Pearson’s correlation coefficient, were 28 swollen joint
count (SJC28), C-reactive protein (CRP), and physician global assessment (PhGA). A matrix model showed that the
predicted risk of radiographic progression was higher with the increased level of SJC28, CRP, and PhGA (P < 0.001).
Conclusions: In this pooled analysis of phase III clinical trial data of biosimilars for RA, identifiable baseline factors
(SJC28, CRP, and PhGA) associated with radiographic progression were similar to those described in prior studies.
Even though radiographic progression was minimal, a small number of patients who have increased SJC28, CRP,
and PhGA at baseline should be closely monitored and follow treat-to-target approach.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic disorder
that causes clinical symptoms as well as structural joint
damage leading to functional disability, poor quality of
life, decreased work productivity, and substantial societal
cost in terms of both direct and indirect costs [1–5].
Achievement of remission or low disease activity re-
mains the overarching goal of therapy, regardless of
whether patients have early or established RA, with
therapeutic decisions guided by the extent of disease ac-
tivity and prognostic factors [6–8]. Reducing joint dam-
age progression, as visualised by radiographic changes, is
important given its correlation with irreversible func-
tional impairment [9, 10]. The biologic disease-
modifying anti-rheumatic drugs (bDMARDs) etanercept,
infliximab, and adalimumab are tumour necrosis factor
(TNF) inhibitors for which RA is among their approved
indications [11–13]. Randomised clinical trials of these
agents in patients with RA have collectively and consist-
ently demonstrated benefits with respect to reducing dis-
ease activity, inhibiting radiographic progression, and
inducing clinical remission, with significant advantages
for combination therapy versus monotherapy with
methotrexate (MTX) or a TNF inhibitor alone [14–
24]. Study extension data are also available and have
demonstrated the long-term efficacy and safety of
TNF inhibitors [25, 26].
Research efforts have identified baseline factors that
are predictive of radiographic progression and provide
clinical value for identifying patients who require inten-
sive treatment and monitoring from the time of diagno-
sis. Prior studies of nonbiologic and bDMARDs have
revealed certain baseline factors associated with radio-
graphic progression, including baseline swollen joint
count (SJC), C-reactive protein (CRP) level, erythrocyte
sedimentation rate (ESR), rheumatoid factor (RF) and
anti-citrullinated peptide antibody (ACPA) status, and
the presence of erosions [27–29]. Disease activity, as
evaluated by composite indices, has also been found to
have a strong association with progression of joint dam-
age [12, 14, 15, 30], though the use of bDMARDs may
result in less radiographic progression than MTX alone
across different disease activity spectrums [15, 31–36].
Risk factors for rapid radiographic progression have
been identified in terms of a matrix risk model more
than a decade ago [28] and since then have been con-
firmed [27, 29, 37]. However, these matrix models
looked at the risk of patients who were either on placebo
with conventional synthetic DMARDs (csDMARDs) like
MTX as background therapy or on newly administered
MTX and compared this with progression in patients
treated with bDMARDs plus MTX. Because radiographic
progression is quite intensive with csDMARDs or pla-
cebo and progression rates were much higher in earlier
years [38], researchers primarily looked at rapid radio-
graphic progression which was defined as an annual pro-
gression rate of ≥ 5 modified Sharp/van der Heijde score
points per year [28, 29]. However, using this definition
can be difficult for patients on anti-TNFs because only a
small number of them have such large radiographic pro-
gression rates while on anti-TNFs, aside from less pro-
gression seen in recent years.
Several previous studies showed a blunted relationship
between the progression of joint damage and clinical dis-
ease activity during the course of treatment with
bDMARDs [15, 31–36], and it has not been clarified yet
whether bDMARDs reduce or halt progression of dam-
age irrespective of disease activity or there is still a strict
relationship to clinical activity. Moreover, having no pro-
gression of joint damage is an important aspect, since it
provides evidence for a full abrogation, and not just
mitigation, of the structural aggressiveness of RA. In the
present study, we used a large database collectively de-
rived across the phase III clinical trials of biosimilars
SB4, SB2, and SB5 and the reference products etaner-
cept, infliximab, and adalimumab, thus encompassing 3
different TNF-inhibitors to look at whether there are




This is a pooled analysis of 3 phase III studies that
compared the efficacy and safety of each biosimilar
TNF inhibitor (SB4, SB2, and SB5) with its associated
reference product (etanercept, infliximab, and
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adalimumab, respectively) [39–41]. All 3 clinical stud-
ies were multicentre, randomised, double-blind, and
parallel-group in design and enrolled patients with
moderately or severely active RA despite MTX treat-
ment, conducted to evaluate the efficacy, pharmaco-
kinetics, safety, and immunogenicity of the biosimilar
in comparison with its reference product in these
patients.
The methodologies of each of the 3 studies have been
published in detail elsewhere [39–41]. The eligibility cri-
teria for these 3 studies were similar, resulting in similar
patient demographics across studies. In brief, patients
were aged 18 to 75 years and had been diagnosed with
RA (per American College of Rheumatology 1987 re-
vised classification criteria, in accordance with the re-
spective comparator trials performed with the original
agents); all patients had a disease duration of ≥ 6 months,
during which they had received MTX for ≥ 6months
and at a stable dosage for ≥ 4 weeks before screening or
randomisation. Additional requirements included the
presence of active disease as evidenced by ≥ 6 swollen
joints and ≥ 6 tender joints and either ESR ≥ 28mm/h or
serum CRP level ≥ 1.0 mg/dL. No prior treatment with
biologic agents was allowed.
Since the effects of all 3 TNF inhibitors on radio-
graphic progression were similar and were also shown to
be similar between originator and biosimilar TNF
blockers [42–44], the data of all trial arms were pooled
and included all patients who had baseline demographic
and disease characteristic data available, as well as radio-
graphic results at baseline and study end (week 52 for
SB4/etanercept and SB5/adalimumab studies, week 54
for the SB2/infliximab study).
Data extraction
Structural joint damage was assessed from x-rays of both
hands and feet. Radiographs were scored at week 0 and
the final study week (week 52 for SB4/etanercept and
SB5/adalimumab studies, week 54 for the SB2/infliximab
study) using the modified Total Sharp Score (mTSS), the
sum of the joint erosion score and the joint space nar-
rowing score [45, 46]. X-rays from week 0 and the final
study week were scored centrally by 2 independent
qualified individuals under blinded conditions. The
mean score for the change in mTSS from the 2 assess-
ments was used for the analysis. Radiographic progres-
sion was defined as a 1-year mean change in mTSS > 0.
Data analysis
Patients with radiographic data, baseline demographics,
and disease characteristics available from each study
were pooled and analysed. The 3 individual baseline fac-
tors most associated with radiographic progression were
identified based on those having the strongest Pearson’s
correlation coefficient with the change in mTSS. Various
demographic (e.g., age and sex) and disease characteris-
tics (e.g., baseline SJC28, CRP, ESR, and RF positivity)
were analysed (see Table 1 for complete list); composite
scores (e.g., Simplified Disease Activity Index [SDAI],
and Clinical Disease Activity Index [CDAI]) were also
analysed, but not selected for baseline factors included
in the matrix. We did not primarily employ Disease Ac-
tivity Score in 28 joints [DAS28] by ESR, since this score
should not anymore be used to define remission accord-
ing to ACR-EULAR remission definitions and newer in-
sights [47, 48]. Univariate logistic regression was
performed to assess the association between each base-
line factor and the proportion of patients with radio-
graphic progression. Multivariate logistic regression was
used to develop the matrix model of the 3 identified in-
dividual baseline factors to show the proportion of pa-
tients with radiographic progression in trichotomised
cutoffs of each baseline factor.
In exploratory analyses, further multivariate logistic
analyses were performed based on the identified 3 base-
line factors using the same dataset to predict the propor-
tion of patients in remission or low disease activity
(LDA) by CDAI, SDAI, and DAS28 at week 24/30. Sep-
arate matrices were built on joint space narrowing and
joint erosion score, subcomponents of mTSS, and for
the proportion of patients with joint erosion score > 0
and joint space narrowing > 0 in trichotomised cutoffs of
each baseline factor.
Results
Overall, the analysis included 1371 patients, 376
(27.4%) of whom experienced radiographic progres-
sion (> 0) with a mean change in mTSS of 0.41 (SD,
3.21). Of note, while on TNF inhibitor therapy, 121
(8.8%) patients had progression of mTSS ≥ 3. Baseline
characteristics for all patients are displayed in Table 1.
For all treatments combined, the mean age of partici-
pants was 51.4 years and most patients were female
(81.7%). The mean duration of RA was 5.9 years, and
mean mTSS was 37.9 at baseline. Based on Pearson’s
correlation coefficient, the SJC28, CRP, and physician
global assessment (PhGA) were determined to be sig-
nificant baseline predictors of radiographic progres-
sion and used for further analysis (Table 1). DAS28,
SDAI, and CDAI were also significant with P values
< 0.05 (Table 1).
Although RF status (positive [> 14 kIU/L] vs negative)
significantly correlated with the presence of radiographic
changes (yes/no) (P = 0.002), it did not significantly cor-
relate with the numerical change in mTSS, which was
the measurement used to extract individual baseline fac-
tors that were most associated based on Pearson’s cor-
relation coefficient (P = 0.7261).
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The predicted risk of radiographic progression as a
function of SJC28, CRP, and PhGA in the all treatments
combined group is shown in Fig. 1a–c. Overall, as
SJC28, CRP, and PhGA increased, the predicted risk of
radiographic progression likewise increased. A similar
pattern was shown for CDAI and SDAI (Supplementary
Fig. 1A, B).
Development of the matrix risk model on radiographic
progression (Fig. 2) showed that the 3 risk factors were
associated with radiographic progression (P < 0.001). The
predicted proportion of patients with radiographic pro-
gression tended to increase as the matrix moved from
the lower to the higher range of each risk factor. As an
example, the proportion of radiographic progressors (pa-
tients with the 1-year change in mTSS > 0) in the group
with the highest cutoff value of SJC28, CRP, and PhGA
was 40.7% (95% CI, 35.2%, 46.5%), whereas the propor-
tion of radiographic progressors in the lowest cutoff
value of SJC28, CRP, and PhGA was 15.5% (95% CI,
12.0%, 19.8%). In the matrix, CRP had a significant asso-
ciation with radiographic progression (P < 0.0001). P
values for SJC28 and the PhGA were 0.139 and 0.140,
respectively.
In the exploratory analysis, the matrix for the subcom-
ponents of mTSS score was developed, and it showed
that the predicted probability of patients with joint
erosion score > 0 or joint space narrowing > 0 increased
as each baseline factor worsened (Supplementary Fig. 2A,
B). Additional analysis was done by disease activity, and
the proportion of patients in remission or LDA by CDAI
at week 24/30 tended to decrease with higher levels of
baseline SJC28, CRP, and PhGA scores (Fig. 3). The pro-
portion of patients in remission or LDA was 34.9% (95%
CI, 29.0%, 41.3%) in the highest baseline cutoff value
(SJC28 > 12, CRP > 11 mg/L, and PhGA > 80mm) and
54.7% (95% CI, 47.8%, 61.4%) in the lowest baseline cut-
off value (SJC28 < 8, CRP < 3.5 mg/L, and PhGA < 50
mm). Additionally, the proportion of patients in remis-
sion or LDA by the SDAI and DAS28 showed a similar
pattern (Supplementary Fig. 3A, B). The total numbers
of patients in each tertile of the 3 baseline factors in the
matrix model are shown in Supplementary Fig. 4.
Discussion
In this pooled study of 1371 patients from the SB4/eta-
nercept, SB2/infliximab, and SB5/adalimumab phase III
studies of biosimilars and originators for the treatment
of RA, radiographic progression, although present, was
minimal overall except a small proportion of patients
with progression. Notably, studies involving conven-
tional synthetic DMARDs have shown more significant
radiographic progression [27–29]. Despite using higher
Table 1 Baseline demographic and disease characteristics
Characteristica Total number of patients
N = 1371
Correlation coefficient P value of Pearson’s correlation coefficient
with the change in mTSS
Baseline mTSS 37.9 (56.8) 0.025 0.36
Age, years 51.4 (12.0) − 0.023 0.39
Female, n (%) 1120 (81.7) 0.032 0.24
RA disease duration, years 5.9 (4.9) 0.0019 0.94
MTX dose, mg/week 15.2 (4.4) − 0.0021 0.94
SJC28 11.0 (5.1) 0.077 0.0041
TJC28 15.1 (6.3) 0.041 0.13
HAQ-DI 1.5 (0.6) 0.049 0.071
DAS28 (ESR) 6.5 (0.8) N/A 0.022
SDAI 39.9 (11.8) N/A 0.004
CDAI 38.5 (11.4) N/A 0.009
PhGA VAS, mm 61.9 (15.5) 0.054 0.048
Patient global assessment VAS, mm 61.9 (18.6) 0.041 0.13
Patient pain assessment VAS, mm 62.0 (19.5) 0.043 0.11
CRP, mg/L 13.3 (19.1) 0.057 0.033
ESR, mm/h 44.4 (20.4) 0.042 0.12
RF positive,b n (%) 1033 (75.4) 0.024 0.73
CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 disease activity score by 28 joint count, ESR erythrocyte sedimentation rate, HAQ-DI health
assessment questionnaire disability index, mTSS modified Total Sharp Score, MTX methotrexate, N/A not applicable, PhGA physician global assessment, RA
rheumatoid arthritis, RF rheumatoid factor, SDAI Simplified Disease Activity Index, SJC28 28 swollen joint count, TJC28 28 tender joint count, VAS visual
analogue scale
aData are presented as mean (SD), unless indicated otherwise
bRF positive indicates > 14 kIU/L for SB4, SB2, and SB5
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Fig. 1 a–c Predicted probability (with 95% confidence limits) of patients with radiographic progression (yes/no) based on a SJC28, b PhGA, and c
CRP. CRP, C-reactive protein; PhGA, physician global assessment; SJC28, 28 swollen joint count
Fig. 2 Matrix model of the proportion of patients with radiographic progression based on SJC28, CRP, and PhGA. Data are presented as % (95%
confidence interval). Predicted probability of patients with radiographic progression represented by shading: green, < 22.0%; yellow, 22.0–32.0%;
red, > 32.0%. CRP, C-reactive protein; SJC28, 28 swollen joint count; PhGA, physician global assessment; VAS, visual analogue scale
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mTSS cutoff values in those studies, the proportion of
patients with radiographic progression was higher, which
reflects the effectiveness of TNF inhibitors in slowing
radiographic progression. Indeed, in previous studies,
the effects on rapid radiographic progression were
assessed [27–29], whereas in this study, we focused on
prediction of any damage progression (mean change in
mTSS > 0) on TNF inhibitors.
Overall, the findings of the current analyses were con-
sistent with those from previous studies based on con-
ventional DMARDs or reference biologics in identifying
CRP levels and SJC28 as significant baseline factors asso-
ciated with radiographic progression in patients receiv-
ing MTX or other csDMARDs [27–29, 37] while RF
levels were not. The use of bDMARDs is known to blunt
the correlation between the baseline disease activities
and radiographic progression [15, 31–33, 35]. Neverthe-
less, we observed that baseline CDAI and SDAI still
showed a relationship with the change in mTSS based
on Pearson’s correlation coefficient (P value 0.004 for
SDAI and 0.009 for CDAI) and predicted probability of
patients with radiographic progression (yes/no) based on
SDAI and CDAI (Supplementary Fig. 1A, B). This is in
line with the data obtained from assessing the individual
components of these composite measures, since it is
postulated from our study that the correlation is due to
CRP, SJC28, and to some extent also PhGA which is
usually a reflection of SJC and CRP [49, 50]. However,
the much stronger significance of the association be-
tween composite measures and radiographic progression
compared with the individual variables once again
confirms the advantage of assessing composite scores.
Fautrel et al. sought to develop a predictive algorithm
and matrix in patients with early RA initiating syn-
thetic DMARD therapy using SJC, CRP level, RF or
ACPA status, and the presence of typical RA erosions
as predictors of radiographic progression that were
applied in the final multivariate model [27]. Data
from clinical trials in which some patients received
infliximab were the first used in the development of
risk models for rapid radiographic progression [28,
29]. More specifically, matrix modelling based on the
ASPIRE study of MTX alone or with infliximab in
MTX-naive early RA was developed using SJC28, RF,
and either CRP or ESR (with the goal of making the
model interchangeable from a clinical practice stand-
point), with treatment arm as a dichotomous variable
[28]. It showed a dramatic structural advantage of
treating patients with a TNFi+MTX vs MTX alone
regarding the risk of rapid radiographic progression.
When that model was expanded to another study of
infliximab (the ATTRACT study of continued MTX
with infliximab or placebo in patients with active RA
despite stable-dose MTX), the use of the combination
was again associated with a low risk of rapid radio-
graphic progression when patients were in the low or
intermediate ranges of the baseline risk factors, with
high risk limited to those patients at the highest base-
line risk ranges. Unlike patients on combination ther-
apy, for patients on MTX monotherapy, risk of rapid
radiographic progression was high irrespective of
baseline risk factors.
Fig. 3 Matrix model of the proportion of patients in remission or low disease activity by CDAI at week 24/30 based on baseline SJC28, CRP, and
PhGA. Data are presented as % (95% confidence interval). Predicted probability of patients in remission or low disease activity represented by
shading: green, > 47.0%; yellow, 40.0–47.0%; red, < 40.0%. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; PhGA, physician global
assessment; SJC28, 28 swollen joint count; VAS, visual analogue scale
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Subsequently, a matrix risk model developed in a post
hoc analysis of the BeSt study (evaluating MTX-based
therapy, including MTX plus infliximab, for recent-onset
RA) confirmed these data by identifying baseline CRP
level, RF/ACPA status, and in addition erosion score as
independent factors for predicting rapid radiographic
progression, defined as an increase in Sharp-van der
Heijde score ≥ 5 after 1 year [29].
Thus, matrix modelling demonstrated risk reduction
with initial combination therapy that included infliximab
or prednisone relative to MTX monotherapy, establish-
ing treatment choice as a main determinant of rapid
radiographic progression. However, in contrast to these
prior risk models that determined risk by treatment arm,
the current analysis did not compare radiographic pro-
gression by product or between biosimilars and refer-
ence products.
The goal of our study was to determine if one could
discern patients at risk for progression of joint damage
while on TNF inhibitors, since joint damage is generally
a sign of aggressive disease and high inflammatory pro-
pensity, especially if cumulative over time.
Therefore, we did not examine rapid radiographic pro-
gression, since it is primarily observed upon administra-
tion of conventional synthetic DMARDs or placebo.
However, since the matrix model shows that TNF inhib-
itors cannot prevent progression in patients at high risk,
such patients may have to receive another treatment
than a TNF-blocker, given their significant progression
on these drugs. The predicted model also showed that
patients with high levels of SJC28, CRP, and PhGA at
baseline also showed slightly increased risk of higher dis-
ease activity by CDAI at week 24/30. Based on this, one
can infer that baseline characteristics have a relationship
with radiographic progression and disease activity. This
further supports the importance of the treat-to-target
approach; if the treatment target of LDA is not met be-
tween weeks 12 to 24, advancing to the next line of ther-
apy is recommended [7]. We also demonstrated an
association between PhGA and radiographic progression
in the setting of RA. In our study, RF levels were not
found to be associated with the change in mTSS at 1-
year and, therefore, it did not become part of the matrix
model. This is likely explained by the fact that anti-TNF
blunts the association between RF status and radio-
graphic progression [51], unlike in the studies on con-
ventional synthetic DMARDs. Of note, the presence of
RF determines disease activity and, therefore, RF appears
to primarily act via increasing inflammation [52–54].
The ACPA status was not available and not included in
the analysis.
This analysis has several limitations. Most notably, the
lack of a placebo or MTX monotherapy group in the
phase III studies precludes prediction of radiographic
progression in reference to no biologic treatment. An-
other limitation is that ACPA status was not obtained in
the study. Additionally, although the phase III studies
had similar designs, patient demographics, and disease
characteristics, they were not primarily designed to be
combined.
To identify baseline factors for patients on anti-TNFs,
a more stringent definition of radiographic progression
compared to previous matrix models [28, 29] was
employed to reveal a halt, and not just a reduction of
damage progression.
Conclusions
Our analysis of phase III clinical trials of biosimilars and
reference products for RA identified baseline factors that
were consistent with those identified for rapid radio-
graphic progression in previous studies of csDMARD
therapy in RA. This signifies that even though radio-
graphic progression is minimal while on anti-TNF, a
small proportion of patients still has significant progres-
sion, and clinicians should closely monitor patients who
have high SJC28, CRP, and PhGA before treatment start
whether they are started on csDMARDs or anti-TNFs.
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